Q3 2026: Psychedelic Drug Development Pipeline
This resource is supported by
We bring translatable neuroscience expertise to the field of psychotherapeutic research. Drawing on experience from 600+ CNS studies, Syneos Health supports complex drug development with scientific depth, operational excellence, integrated trial delivery and risk management insight.
Advance Psychedelic BreakthroughsDownload a PDF Copy
If you would like to receive a high-resolution PDF of the bullseye charts, please enter your email below to join our free newsletter.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Q3 2026 Psychedelic Drug Development Bullseye Chart
Q3 2026 Psychedelic Drug Development Bullseye Chart, segmented by molecule group.
By Indication Grouping
Q3 2026 Psychedelic Drug Development Bullseye Chart, segmented by indication grouping.
Download a PDF Copy
If you would like to receive a high-resolution PDF of the bullseye charts, please enter your email below to join our free newsletter.
By signing up, you agree to our privacy policy. You can unsubscribe at any time.
Order a Poster
You can order poster copies of our Bullseye Charts to your office of home, at cost price.